Connecticut is currently home to 1268 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer
Register for Updates
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
NCT05204563
Recruiting
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2023
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Register for Updates
Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations
NCT04848051
Recruiting
The purpose of this study is to understand best strategies for engaging high risk populations in a primary care setting to improved adherence to colorectal cancer screening guidelines. The results will be used to identify best practices that are scalable to other high-risk populations who are due or overdue for colorectal cancer (CRC) screening.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
03/01/2023
Locations: Cornell Scott Hill Health Center, New Haven, Connecticut
Conditions: Colorectal Cancer
Register for Updates
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT02926690
Recruiting
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Norwalk Hospital, Norwalk, Connecticut
Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Register for Updates
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Acquiring and Targeting Heat Exposures Necessary for Action
NCT05678738
Recruiting
The purpose of this research study is to better understand ways that women and men differ physiologically, cognitively, physically, and cellularly to better prescribe helpful interventions that will prevent injury and risk of conditions like exertional heat illnesses or heatstroke. The main questions this project aims to answer are: What is the relative stress contributing to performance differences between women and men during intense exercise in extremely hot and humid environments in respons... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
12/28/2022
Locations: Human Performance Laboratory at the University of Connecticut, Storrs, Connecticut
Conditions: Heat Intolerance, Heat Stress, Fatigue; Heat
Register for Updates
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
NCT05314764
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT04931823
Recruiting
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/16/2022
Locations: Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumor
Register for Updates
Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System
NCT04881162
Recruiting
Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2022
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Ischemic Stroke
Register for Updates
AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
NCT04663867
Recruiting
The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO Crossing System.
Gender:
All
Ages:
22 years and above
Trial Updated:
11/22/2022
Locations: Vascular Care Connecticut, Darien, Connecticut
Conditions: Peripheral Artery Occlusion, Peripheral Arterial Disease
Register for Updates
StimRouter Registry Clinical Protocol
NCT03913689
Recruiting
This Registry study will prospectively evaluate the long-term effectiveness, safety, and tolerability of the StimRouter Neuromodulation System, along with evaluating the technical performance of StimRouter, surgical outcomes, health-related quality of life, concomitant medical use, and subject's impression of improvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2022
Locations: Stamford Hospital, Stamford, Connecticut
Conditions: Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Register for Updates
Cognitive Fitness for Depression in Older Adults
NCT04790630
Recruiting
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants. The investigators are also interested in whether participating in the treatment will result in changes to brain activity measured with magnetic resonance imaging (MRI).
Gender:
All
Ages:
60 years and above
Trial Updated:
11/02/2022
Locations: UConn Health, Farmington, Connecticut
Conditions: Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Register for Updates